The U.S. Food and Drug Administration (FDA) has approved Komzifti (ziftomenib), which is a type of treatment known as a menin ...

CEO Sergio Traversa highlighted a "standout year" for Relmada, citing "excellent product development progress" and a "recent successful capital raise." He emphasized the advancement of two clinical ...

Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) ...

Typically, the ammunition to bring down an entire genre of movies is a series of box office flops. There can be other ...

Q3 2025 Earnings Call Transcript November 12, 2025 Autolus Therapeutics plc misses on earnings expectations. Reported EPS is ...

The approval was based on data from the single-arm, open-label phase 2 KOMET-001 trial, which evaluated ziftomenib, a menin inhibitor, in adults with R/R AML with an NPM1 mutation.

Ulcerative colitis is a chronic, immune-mediated disorder of the colon, which is characterised by a relapsing–remitting course. Owing to the growing understanding of the immunopathogenesis of this ...

Received $54.6 Million in Gross Proceeds from Warrant Exercises: In September and October 2025, SELLAS received a total of approximately $54.6 million in gross proceeds from the immediate exercise of ...

ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safety allows for ...

Good morning, ladies and gentlemen, and welcome to the Cellectar Biosciences' Third Quarter 2025 Earnings Call. [Operator Instructions] This call is being recorded on Thursday, November 13, 2025. I ...

Nalgonda: Holding Narketpally-based Kamineni Hospital liable for medical negligence leading to the death of a patient during ...

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ('BioVaxys” or the 'Company”) announces an extension of its non-brokered private placement financing (the 'Offering”) previously announced on October 7 ...